Ena Respiratory

ENA Respiratory is a clinical-stage pharmaceutical company developing INNA-051, an intranasal innate immune modulator for the prevention of complications resulting from respiratory viral infections in at-risk populations, including older adults, those with co-morbidities (COPD, asthma, diabetes, and cardiovascular disease) and individuals with occupational risk. The ENA team has a long history of successful drug development in respiratory diseases and seeks to leverage this expertise to meet the considerable unmet need that still exists for these vulnerable populations. ENA Respiratory has partnered with the COPD Foundation to enable and optimize patient-centered clinical development of INNA-051 in COPD. In 2022, it joined BLUE KNIGHT™, a joint initiative between Johnson & Johnson Innovation and BARDA designed to accelerate development of potential solutions for future pandemics. In 2023, the company was awarded a $8.18 million contract from the U.S. Department of Defense to support the continued development of INNA-051.